Immunotech Biopharm Ltd
永泰生物製藥有限公司
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 6978)

VOLUNTARY ANNOUNCEMENT
BUSINESS UPDATE – RECENT DEVELOPMENT OF EAL®

This announcement is made by Immunotech Biopharm Ltd. (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis to inform the shareholders and potential investors of the Company regarding the recent business updates of the Group.

The board of directors (the "**Board**") and the directors (the "**Directors**") of the Company hereby announce that, based on the Group's recent communication with the Center for Drug Evaluation (the "**CDE**") of the National Medical Products Administration (the "**NMPA**") of the People's Republic of China, the CDE has agreed that the Group may submit an application for conditional approval for its core product candidate, EAL®.

The Company reminds that, following the planned submission of the new drug application, such application and the information submitted will be subject to aggressive scrutiny and evaluation by the CDE, which may terminate the application earlier at any time or reject it immediately if the results were determined to be unsatisfactory upon review. The Company emphasizes that the submission, timetable, contents and final approval of any such application may or may not materialize depending on a number of factors, including further communication with regulatory authorities, progress of registration verification and compliance with the regulatory requirements for conditional approval.

As at the date of this announcement, the Group has not yet submitted any new drug application in relation to EAL®, which is expected to be submitted in the near future. An announcement will be published by the Company in due course upon acceptance of the application by the CDE.

INFORMATION ON EAL®

EAL® is a multi-target cellular immunotherapy product with more than a decade of track record of clinical application in the treatment of cancer. EAL® is a preparation of activated and expanded T cells originally taken from a patient's autologous peripheral blood and cultured using patented methods. The main active component of the product is CD8+ cytotoxic T cells, whose surface marker is the CD3 molecule. As at the date of this announcement, the Company has completed the enrollment of 430 target patients for the Phase II clinical trial.

ABOUT THE GROUP

The Group is a leading cellular immunotherapy biopharmaceutical company in China focusing on the research, development, and commercialisation of T cell immunotherapy. Since its establishment in 2006, it has focused on research and development and clinical applications of cellular immunotherapy drugs for cancers and other major diseases, by applying advanced theories in immunology, cell biology, and genetics.

Its product pipeline features major classes of cellular immunotherapy products, including both non-genetically-modified and genetically-modified products, as well as both multi-target and single-target products. Its main product candidates include EAL®, the CAR-T cell series and the TCR-T cell series. To learn more about the Company, please visit www.eaal.net.

Cautionary Statement required by Rule 18A.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: The Group cannot guarantee that the Company will be able to obtain further approval for, or ultimately market, EAL®, successfully. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Immunotech Biopharm Ltd
Tan Zheng
Chairman and executive Director

Hong Kong, 28 February 2025

As at the date of this announcement, the Board comprises Mr Tan Zheng as Chairman and executive Director, Dr Wang Yu as executive Director, Mr Tao Ran, Mr Wang Ruihua, Mr Yang Fan and Mr Wang Donghu as non-executive Directors, and Professor Wang Yingdian, Mr Ng Chi Kit and Ms Peng Sujiu as independent non-executive Directors.